Alpha Cognition Inc. (ACOG) – What Are Researchers Thinking About This Stock?

Alpha Cognition Inc. (NASDAQ:ACOG) has earned a consensus rating of “Buy” from the five research firms that are presently covering the firm, Marketbeat reports. Five equities research analysts have rated the stock with a buy rating. The average twelve-month price target among analysts that have issued ratings on the stock in the last year is $18.00.

Several research analysts have recently commented on ACOG shares. Wall Street Zen upgraded shares of Alpha Cognition from a “sell” rating to a “hold” rating in a research note on Saturday, August 15th. B. Riley Financial assumed coverage on shares of Alpha Cognition in a research note on Thursday, August 20th. They issued a “buy” rating and a $21.00 price objective for the company. Craig Hallum reaffirmed a “buy” rating and issued a $17.00 price objective on shares of Alpha Cognition in a research note on Friday, August 14th. HC Wainwright upped their price objective on shares of Alpha Cognition from $18.00 to $20.00 and gave the stock a “buy” rating in a report on Monday, August 17th. Finally, Raymond James Financial began coverage on shares of Alpha Cognition in a research report on Friday, July 10th. They set an “outperform” rating and a $20.00 target price on the stock.

Alpha Cognition Stock Performance

NASDAQ:ACOG opened at $8.65 on Thursday. The stock’s 50 day moving average price is $9.02 and its 200 day moving average price is $7.58. Alpha Cognition has a 52 week low of $4.50 and a 52 week high of $10.14.

Alpha Cognition (NASDAQ:ACOG) last issued its quarterly earnings data on Thursday, August 13th. The company reported ($0.40) earnings per share for the quarter, missing the consensus estimate of ($0.39) by ($0.01). The business had revenue of $6.00 million for the quarter, compared to the consensus estimate of $4.38 million. Alpha Cognition had a negative net margin of 153.61% and a negative return on equity of 54.60%. On average, equities research analysts predict that Alpha Cognition will post -1.38 earnings per share for the current year.

Insider Buying and Selling at Alpha Cognition

In related news, Director Robert Wills purchased 10,000 shares of Alpha Cognition stock in a transaction on Friday, August 21st. The stock was bought at an average price of $9.62 per share, with a total value of $96,200.00. Following the completion of the transaction, the director directly owned 32,241 shares of the company’s stock, valued at approximately $310,158.42. This represents a 44.96% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. 8.60% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in the stock. Opaleye Management Inc. raised its position in shares of Alpha Cognition by 13.0% in the second quarter. Opaleye Management Inc. now owns 2,895,467 shares of the company’s stock valued at $20,905,000 after purchasing an additional 333,517 shares during the period. AWM Investment Company Inc. bought a new position in Alpha Cognition in the 2nd quarter worth $12,073,000. Aristides Capital LLC boosted its holdings in Alpha Cognition by 1.4% during the first quarter. Aristides Capital LLC now owns 218,510 shares of the company’s stock valued at $1,200,000 after acquiring an additional 3,052 shares during the period. Finally, ACT Capital Management LLC bought a new position in shares of Alpha Cognition in the fourth quarter worth about $335,000.

Alpha Cognition Company Profile

Alpha Cognition Inc (NASDAQ: ACOG) is a biopharmaceutical company focused on developing and commercializing treatments for neurodegenerative disorders, including Alzheimer’s disease and related cognitive conditions. The company’s work is centered on addressing unmet needs in the diagnosis, management and treatment of diseases that affect memory and cognitive function.

Its lead commercial product is ZUNOVO (memantine hydrochloride extended-release capsules), a prescription therapy approved by the U.S.